{
    "id": "d77f3b2f-eda8-45ae-8455-0fc1694fcd54",
    "indications": {
        "text": "andexxa indicated patients treated rivaroxaban apixaban , reversal anticoagulation needed due life-threatening uncontrolled bleeding . indication approved accelerated approval based change baseline anti-fxa activity healthy volunteers [ ( 14 ) ] . improvement hemostasis established . continued approval indication may contingent upon results demonstrate improvement hemostasis patients .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "intravenous ( iv ) . \u2022 dose andexxa based fxa inhibitor , dose fxa inhibitor , time since patient 's last dose fxa inhibitor . ( 2 ) \u2022 administer iv bolus , target rate 30 mg/min , followed continuous infusion 120 minutes . ( 2.3 ) \u2022 two dosing regimens : dose safety effectiveness one dose evaluated . ( 2.1 ) initial iv bolus follow-on iv infusion low dose 400 mg target rate 30 mg/min 4 mg/min 120 minutes high dose 800 mg target rate 30 mg/min 8 mg/min 120 minutes",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "adverseReactions": "none .",
    "ingredients": [
        {
            "name": "andexanet alfa",
            "code": "BI009E452R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14562"
        }
    ],
    "organization": "AstraZeneca Pharmaceuticals LP",
    "name": "ANDEXXA",
    "effectiveTime": "20250523",
    "indications_original": "ANDEXXA is indicated for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.\n                  This indication is approved under accelerated approval based on the change from baseline in anti-FXa activity in healthy volunteers [see Clinical Studies (14)]. An improvement in hemostasis has not been established.  Continued approval for this indication may be contingent upon the results of studies that demonstrate an improvement in hemostasis in patients.",
    "contraindications_original": "For intravenous (IV) use only. \u2022 Dose ANDEXXA based on the specific FXa inhibitor, dose of FXa inhibitor, and time since the patient's last dose of FXa inhibitor. ( 2 ) \u2022 Administer as an IV bolus, with a target rate of 30 mg/min, followed by continuous infusion for 120 minutes. ( 2.3 ) \u2022 There are two dosing regimens: Dose The safety and effectiveness of more than one dose have not been evaluated. ( 2.1 ) Initial IV Bolus Follow-On IV Infusion Low Dose 400 mg at a target rate of 30 mg/min 4 mg/min for 120 minutes High Dose 800 mg at a target rate of 30 mg/min 8 mg/min for 120 minutes",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "ANDEXXA",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14562"
        }
    ]
}